🔓 Unlock the full profile of Dan Connelly (Thermo Fisher Scientific), including verified contact details, financial insights, and professional associations.
See Dan Connelly Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: dan*****@the******.com
Mobile: 67167*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Dan Connelly currently serves as the Biosciences Account Manager at Thermo Fisher Scientific in Boston, Massachusetts.
- In addition to account management, Dan is the Chapter Lead and Founder of the Greater Boston PossAbilities Business Resource Group, emphasizing inclusion and support for employees with disabilities.
- Dan began their career with Thermo Fisher Scientific as an Associate Sales Representative in the Laboratory Products Division in July 2019, showcasing a progressive career trajectory within the organization.
- In February 2021, Dan transitioned to the role of Territory Sales Representative for Laboratory Plastic Essentials, further expanding expertise in sales for laboratory products.
- By March 2022, Dan achieved the position of Biosciences Account Manager, reflecting significant professional development and a commitment to advancing in the biosciences field.
- Prior to Thermo Fisher, Dan contributed to Vericel Corporation, holding positions such as Compliance Specialist and Senior Manufacturing Technician, gaining valuable experience in regulatory compliance and manufacturing processes.
- Dan's early career included roles in event management and as an undergraduate research assistant, underscoring a diverse skillset and commitment to operational excellence.
- Thermo Fisher Scientific, founded in 2006, has grown to a significant presence in the biosciences sector, known for its innovation and commitment to life sciences, with a market cap of $155.1B.
- The organization boasts a robust growth in headcount over the past two years, reflecting its position as a leader in the biotechnology and pharmaceutical sectors.